share_log

Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $6.5

Benzinga ·  Jul 9 10:45

Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target from $22.5 to $6.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment